Business
genedrive plc (GDR): Preventing hearing loss in...
genedrive plc (GDR): Preventing hearing loss in....
About this update from Genedrive Plc
[{"type":"text","content":"\n \nHardman & Co ResearchHardman & Co Research: genedrive plc (GDR): Preventing hearing loss in newborns27-Jun-2018 / 07:15 GMT/BST\nHardman & Co: Preventing hearing loss in newborns\n\ngenedrive plc (GDR) is a commercial-stage company focused on point-of-care molecular diagnostics. Its Genedrive(R) molecular diagnostic testing platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity and specificity in infectious disease diagnosis. Rapid analysis of patient samples greatly aids clinical and public health decision-making, with field testing particularly important in emerging markets. GDR has been awarded a £550k grant from the UK's National Institute for Health Research (NIHR) to develop a diagnostic to prevent hearing loss resulting from adverse reactions to gentamicin.\n\nPlease click here for the full report:\n\nhttp://hardmanandco.com/docs/default-source/company-docs/genedrive-plc-documents/27.06.18-preventing-hearing-loss-in-newborns.pdf \n\nTo contact us:Hardman & Co35 New Broad StreetLondonEC2M 1NHwww.hardmanandco.comFollow us on Twitter @HardmanandCo\n Contacts:Dr Martin HallDr Dorothea HillDr Gregoire Pave+44 20 7194 7622\n [email protected]@[email protected]\n \n \n\nHardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.\n\nAbout Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.\n\nHardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.\n\nOur resear...